Key Research Statistics
Sleep Architecture & Recovery
59%Sleep IncreaseWithin 130 minutes — human RCT (Schneider-Helmert 1983)
3–7 moEffect Persistence15-minute plasma half-life → months of benefit. Paradoxical duration.
No LD50No Lethal Dose FoundEndogenous nonapeptide — 45+ years, zero dependence or tolerance
Clinical Efficacy Across Conditions
Opiate Withdrawal Relief97%
Alcohol Withdrawal Relief87%
Chronic Pain Reduction86%
Sleep Onset Improvement59%
n=107 (opiate), clinical surveillance (alcohol), n=7 (pain)
DSIP at the Cellular Level
Delta sleep-inducing peptide

DSIP in the Body
Delta sleep-inducing peptide

Complete Your Protocol
Complementary compounds from other research areas






